Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

39.53 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited Ordinary Shares

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

35 36 Next >

How A Small Indian Firm Firm Was Pulled Into A Legal Battle with Big Pharma Over A Cancer Drug ↗

September 11, 2023

This story was first published on the Benzinga India portal.

Via Benzinga

Bristol Myers' Antitrust Allegations: Lawsuit Over Alleged Patent Deception For Blood Cancer Drug ↗

September 07, 2023

Bristol Myers Squibb Co (NYSE: BMY) faces fresh allegations in a recent lawsuit, accused of employing deceptive patents and illicit strategies to preserve its dominant position in the blood cancer drug...

Via Benzinga

Topics Intellectual Property Lawsuit

Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference

September 06, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023

September 06, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Takes A Run At Its 200-Day Line After Second-Quarter Beat And Raise ↗

August 02, 2023

The company also raised the lower boundary of its guidance for full-year sales.

Via Investor's Business Daily

3 Bargain Stocks to Buy on the Dip ↗

June 17, 2023

These stocks should be poised to rebound.

Via The Motley Fool

S&P Slashes Ratings Of Five US Banks, SEC Fines Fintech Adviser Titan For Misleading Crypto Claims, Microsoft Modifies Activision Blizzard Purchase: Today's Top Stories ↗

August 22, 2023

Benzinga

Via Benzinga

Topics Regulatory Compliance Stocks

Big Pharma Price-Fixing: Teva and Glenmark's $255M Settlement Shines Light on Industry Issues ↗

August 22, 2023

Drugmaker Teva Pharmaceutical Industries Limited (NYSE: TEVA) has

Via Benzinga

Teva Settles Price Fixing Charges With U.S. DOJ

August 21, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

FDA Greenlights Expanded Use Of Neurocrine Biosciences' Ingrezza: Analysts Weigh In Depression Warning ↗

August 21, 2023

The FDA approved Neurocrine Biosciences Inc's (NASDAQ: NBIX) Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated

Via Benzinga

Supreme Court Halts Purdue Pharma's $6B Settlement: Sackler Family's Shield From Opioid Lawsuits Challenged ↗

August 10, 2023

On Thursday, the Supreme Court temporarily blocked a $6-billion bankruptcy settlement by Purdue Pharma, the maker of the opioid OxyContin, that would shield the Sackler family from civil lawsuits...

Via Benzinga

Topics Bankruptcy Lawsuit

Teva Pharmaceutical, Marathon Oil And 2 Other Stocks Insiders Are Selling ↗

August 10, 2023

The Nasdaq 100 closed lower by over 1% on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Teva Pharmaceutical Industries (TEVA) Q2 2023 Earnings Call Transcript ↗

August 02, 2023

TEVA earnings call for the period ending June 30, 2023.

Via The Motley Fool

Humana, Waters, e.l.f. Beauty, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday ↗

August 02, 2023

U.S. stocks traded lower, with the Dow Jones falling around 200 points on Wednesday. Here are some big stocks recording gains in today’s session. Powell Industries, Inc. (NASDAQ: POWL) shares jumped...

Via Benzinga

Why Exact Sciences Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

August 02, 2023

Gainers WaveDancer, Inc. (NASDAQ: WAVD) shares climbed 86% to $0.5505. Tellenger, a subsidiary of Wavedancer, Inc., won a seven-year U.S. government contract.

Via Benzinga

Teva Pharma's Stock Soars On Q2 Profit Beat, Highlights Strong Growth From Austedo ↗

August 02, 2023

Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) Q2 sales reached $3.88 billion, up 2% Y/Y (4% on constant currency), slightly beating the

Via Benzinga

Teva Reports Second Quarter 2023 Financial Results

August 02, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development

July 27, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List ↗

July 26, 2023

The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen

Via Benzinga

Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership

July 24, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership

July 24, 2023

From Alvotech

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

July 11, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023 ↗

July 06, 2023

Via Benzinga

Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023

July 05, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva's Strategic Evaluation: Israeli Pharma Company Mulls Divesting $2B Active Ingredients Unit ↗

July 05, 2023

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is reportedly considering potential strategic options for its active pharmaceutical ingredients (API) unit, which could include a potential sale.

Via Benzinga

Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine

June 30, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Geopolitical Risks Prevail ↗

June 27, 2023

A discussion about current geopolitical risks and their impact on commodity and stock markets.

Via Talk Markets

ADHD Medication Shortage Worsens, Vyvanse Supply Dwindles Amid Adderall Scarcity ↗

June 21, 2023

The supply of an alternative to Adderall, Vyvanse (lisdexamfetamine), a commonly used medication for Attention-deficit/hyperactivity disorder (ADHD), is dwindling, further limiting options for patients...

Via Benzinga

Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients

June 15, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Reaches Agreement With Kentucky to Settle the State’s Price Fixing Claims

June 12, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.